News coverage about Integra Lifesciences (NASDAQ:IART) has trended somewhat positive recently, according to Accern. Accern rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Integra Lifesciences earned a news impact score of 0.19 on Accern’s scale. Accern also gave news coverage about the life sciences company an impact score of 46.2398552045215 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
Shares of Integra Lifesciences (NASDAQ IART) traded up $0.10 on Friday, reaching $50.57. 352,799 shares of the company’s stock traded hands, compared to its average volume of 505,972. Integra Lifesciences has a 1-year low of $40.51 and a 1-year high of $56.42. The firm has a market capitalization of $3,960.76, a P/E ratio of 82.90, a P/E/G ratio of 1.68 and a beta of 0.65. The company has a current ratio of 4.49, a quick ratio of 3.39 and a debt-to-equity ratio of 1.26.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.02). Integra Lifesciences had a net margin of 4.52% and a return on equity of 16.35%. The firm had revenue of $278.83 million for the quarter, compared to analyst estimates of $286.00 million. During the same quarter in the prior year, the firm earned $0.93 earnings per share. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. equities analysts expect that Integra Lifesciences will post 1.85 earnings per share for the current year.
IART has been the subject of a number of analyst reports. Oppenheimer reiterated a “buy” rating and issued a $60.00 price target on shares of Integra Lifesciences in a research report on Monday, September 18th. Zacks Investment Research upgraded shares of Integra Lifesciences from a “hold” rating to a “buy” rating and set a $57.00 price target for the company in a research report on Tuesday, October 3rd. Jefferies Group reiterated a “buy” rating and issued a $58.00 price target on shares of Integra Lifesciences in a research report on Thursday, October 12th. JPMorgan Chase & Co. downgraded shares of Integra Lifesciences from an “overweight” rating to a “neutral” rating and set a $44.00 price target for the company. in a research report on Friday, October 27th. Finally, TheStreet downgraded shares of Integra Lifesciences from a “b” rating to a “c+” rating in a research report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $52.70.
In other news, Director Barbara B. Hill acquired 10,768 shares of the stock in a transaction on Tuesday, October 31st. The stock was acquired at an average cost of $46.66 per share, for a total transaction of $502,434.88. Following the completion of the transaction, the director now directly owns 55,540 shares in the company, valued at $2,591,496.40. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Richard D. Gorelick sold 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total transaction of $70,785.00. Following the transaction, the vice president now owns 21,665 shares of the company’s stock, valued at $1,022,371.35. The disclosure for this sale can be found here. 21.50% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Integra Lifesciences (IART) Earns Daily Media Sentiment Score of 0.19” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/14/integra-lifesciences-iart-earns-daily-media-sentiment-score-of-0-19.html.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.